These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 20112435)

  • 1. Predicting the risk of hyperkalemia in patients with chronic kidney disease starting lisinopril.
    Johnson ES; Weinstein JR; Thorp ML; Platt RW; Petrik AF; Yang X; Anderson S; Smith DH
    Pharmacoepidemiol Drug Saf; 2010 Mar; 19(3):266-72. PubMed ID: 20112435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyperkalemia After Initiating Renin-Angiotensin System Blockade: The Stockholm Creatinine Measurements (SCREAM) Project.
    Bandak G; Sang Y; Gasparini A; Chang AR; Ballew SH; Evans M; Arnlov J; Lund LH; Inker LA; Coresh J; Carrero JJ; Grams ME
    J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28724651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of angiotensin-converting enzyme inhibitors in patients with heart failure and renal insufficiency: how concerned should we be by the rise in serum creatinine?
    Ahmed A
    J Am Geriatr Soc; 2002 Jul; 50(7):1297-300. PubMed ID: 12133029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyperkalemia and renin-angiotensin aldosterone system inhibitor therapy in chronic kidney disease: A general practice-based, observational study.
    Jun M; Jardine MJ; Perkovic V; Pilard Q; Billot L; Rodgers A; Rogers K; Gallagher M
    PLoS One; 2019; 14(3):e0213192. PubMed ID: 30845156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D).
    Fried LF; Duckworth W; Zhang JH; O'Connor T; Brophy M; Emanuele N; Huang GD; McCullough PA; Palevsky PM; Seliger S; Warren SR; Peduzzi P;
    Clin J Am Soc Nephrol; 2009 Feb; 4(2):361-8. PubMed ID: 19118120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence of hyperkalemia in high risk patients during treatment with an angiotensin converting enzyme inhibitor (Lisinopril) versus an angiotensin II receptor blocker (Losartan).
    Zanabli AR; Yango A; Dworkin L
    S D J Med; 2004 Jun; 57(6):227-31. PubMed ID: 15253477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toleration of high doses of angiotensin-converting enzyme inhibitors in patients with chronic heart failure: results from the ATLAS trial. The Assessment of Treatment with Lisinopril and Survival.
    Massie BM; Armstrong PW; Cleland JG; Horowitz JD; Packer M; Poole-Wilson PA; Rydén L
    Arch Intern Med; 2001 Jan; 161(2):165-71. PubMed ID: 11176729
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kidney Function and Potassium Monitoring After Initiation of Renin-Angiotensin-Aldosterone System Blockade Therapy and Outcomes in 2 North American Populations.
    Parikh RV; Nash DM; Brimble KS; Markle-Reid M; Tan TC; McArthur E; Khoshniat-Rad F; Sood MM; Zheng S; Pravoverov L; Nesrallah GE; Garg AX; Go AS
    Circ Cardiovasc Qual Outcomes; 2020 Sep; 13(9):e006415. PubMed ID: 32873054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of angiotensin converting enzyme inhibitors and angiotensin receptor blockers on serum potassium levels and renal function in ambulatory outpatients: risk factors analysis.
    Maddirala S; Khan A; Vincent A; Lau K
    Am J Med Sci; 2008 Oct; 336(4):330-5. PubMed ID: 18854676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors for repeated hyperkalemia and potassium trajectories in high-risk patients - A population-based cohort study.
    Adelborg K; Nicolaisen SK; Hasvold P; Palaka E; Pedersen L; Thomsen RW
    PLoS One; 2019; 14(6):e0218739. PubMed ID: 31226134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discontinuation of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Chronic Kidney Disease.
    Qiao Y; Shin JI; Sang Y; Inker LA; Secora A; Luo S; Coresh J; Alexander GC; Jackson JW; Chang AR; Grams ME
    Mayo Clin Proc; 2019 Nov; 94(11):2220-2229. PubMed ID: 31619367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of dual blockade of the renin-angiotensin system in primary proteinuric nephropathies.
    Luño J; Barrio V; Goicoechea MA; González C; de Vinuesa SG; Gómez F; Bernis C; Espinosa M; Ahijado F; Gómez J; Escalada P
    Kidney Int Suppl; 2002 Dec; (82):S47-52. PubMed ID: 12410855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum potassium in stage 5 CKD patients on their first presentation in a dialysis service of a county hospital in western Romania.
    Gluhovschi G; Mateş A; Gluhovschi C; Golea O; Gădălean F; Somai M; Ene I; Petrica L; Velciov S
    Rom J Intern Med; 2014; 52(1):30-8. PubMed ID: 25000676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors. How much should we worry?
    Reardon LC; Macpherson DS
    Arch Intern Med; 1998 Jan; 158(1):26-32. PubMed ID: 9437375
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum Potassium, End-Stage Renal Disease and Mortality in Chronic Kidney Disease.
    Nakhoul GN; Huang H; Arrigain S; Jolly SE; Schold JD; Nally JV; Navaneethan SD
    Am J Nephrol; 2015; 41(6):456-63. PubMed ID: 26228532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence of and Risk Factors for Severe Adverse Events in Elderly Patients Taking Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers after an Acute Myocardial Infarction.
    Fang G; Annis IE; Farley JF; Mahendraratnam N; Hickson RP; Stürmer T; Robinson JG
    Pharmacotherapy; 2018 Jan; 38(1):29-41. PubMed ID: 29059475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is Chronic Kidney Disease Progression Influenced by the Type of Renin-Angiotensin-System Blocker Used?
    Silvariño R; Rios P; Baldovinos G; Chichet MA; Perg N; Sola L; Saona G; De Souza N; Lamadrid V; Gadola L
    Nephron; 2019; 143(2):100-107. PubMed ID: 31203280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms of impaired potassium handling with dual renin-angiotensin-aldosterone blockade in chronic kidney disease.
    Preston RA; Afshartous D; Garg D; Medrano S; Alonso AB; Rodriguez R
    Hypertension; 2009 May; 53(5):754-60. PubMed ID: 19307466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors.
    Weir MR; Rolfe M
    Clin J Am Soc Nephrol; 2010 Mar; 5(3):531-48. PubMed ID: 20150448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined angiotensin inhibition for the treatment of diabetic nephropathy.
    Fried LF; Emanuele N; Zhang JH; Brophy M; Conner TA; Duckworth W; Leehey DJ; McCullough PA; O'Connor T; Palevsky PM; Reilly RF; Seliger SL; Warren SR; Watnick S; Peduzzi P; Guarino P;
    N Engl J Med; 2013 Nov; 369(20):1892-903. PubMed ID: 24206457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.